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PHYSIOLOGy1 
Erythropoietin (EPO) is a 34000 Dalton glycoprotein hormone produced for 90 % by the 
kidney. EPO secretion occurs in response to hypoxic stimuli such as a decrease in 
circulating red cel! volume, low 02 hemoglobin saturation, low blood flow in renal artery, 
bya regulatory process responding to a low 02 concentration in the renal vein. 
EPO is active on the erythropoietic lineage of the bone marrow, with a mitogenic effect 
on BFU-E, CFU-E, proerythroblasts and basophilie erythroblasts. Moreover, EPO also 
increases the rate of differentiation of CFU-E into proerythroblasts. 
EPO elimination is essentially made by the hormone target cells, but a sm ail part of it 
can be found in the urine. 
Serum EPO levels, as detected by RIA or ELISA methods, have to be analyzed in 
relation to the hematocrit (Hct). In ail types of anemia a slow increase in serum EPO 
concentration can be observed until Hct decreases to about 38 %, and below this point 
EPO increases exponentially. In some situations EPO can augment in an appropriate 
manner but with no relation to the actual Hct (respiratory failure, congenital cardiopathy, 
high affinity hemoglobin). The opposite can also occur, with a low EPO level, inadequate 
for the degree of anemia, for instance in chronic renal failure, post-nephrectomy, chronic 
disorders (rheumatoid arthritis, AlOS), or in some malignant diseases. 
PHARMACOLOGICAL USE OF EPO 
Bioengineering techniques have made large amounts ofrecombinant EPO production, 
available for clinical use since about 1985. 
Routes of Administration.2 
The most utilized routes to administer EPO are subcutaneous (SC) and intravenous 
(IV) routes, each possessing particular kinetics, advantages or disadvantages. Compared 
with SC, the IV route produces higher plasmatic EPO concentrations and bioavailability, 
and a larger area under the curve of concentration vs time, but a faster disappearance 
from circulation. In contrast, EPO requirements to obtain the same clinical elfect are 50 to 
60 % lower in patients treated SC. These facts indicate that SC kinetics is better than IV 
because of lower peak concentrations and longer residence time of EPO in human 
plasma, which are closer to the physiological profile of the hormone. 
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Clinicat Use 
The indication of choice of recombinant human EPO is the treatment of the anemia of 
patients with chronic renal failure on dialysis. Usual doses are 40-100 U/Kg SC, three 
times weekly. The dose must be adjusted until a target hematocrit is obtained (usually 
30%). Side effects are rare but are seen with high doses which can cause hypertension 
even accompanied by seizures.These reactions appear to be due to the hemodynamic 
adaptation to an increasing circulating red cell mass. Rare instances of thrombosis of the 
arteriovenous fistula have been described but this has been attributed to a quick increase 
in Hct and/or blood viscosity3. The use of EPO has made it possible to cease transfusions 
in these patients, avoiding transfusion-associated risks of viral disease transmission, 
sensitization, and iron overload. Particular attention must be paid to correcting iron or 
vitamin carency, aluminum intoxication, hyperparathyroidism, and to the treatment of any 
infectious disease. These situations may lower the response to EPO administration3,4 
Other therapeutic applications could be mentioned, as the treatment of the anemia of 
patients with renal failure, but not on dialysis, in whom EPO seems to correct the anemia 
without altering the renal function. Other studies have also demonstrated that larger doses 
of EPO are able to correct the anemia in patients with ma lignant diseases, AlOS or 
rheumatoid arthritis. 
APPLICATIONS IN SURGERY AND AUTOTRANSFUSION 
We reviewed published studies and case reports on the possible use of EPO in 
perisurgical situations, with or without autologous blood (AB) donation. In patients in which 
neither AB nor homologous blood (HB) transfusion are possible, EPO given preoperatively 
seems to contribute to increase the circulating red cell mass prior to surgery, reducing the 
probability of red cell transfusions. Data about the postoperative use of EPO seem to be 
insufficient for the moment, but studies are ongoing and the results will probably be 
available in a short time. 4 
For patients included in AB predonation programs, the following arguments can help to 
understand the possible role of EPO treatment as a complementary approach. First of ail, 
it is quite clear that some percentage of the patients in AB donation programs do not 
complete their procedure because of anemia, and that these patients have a higher 
probability to receive HB in their perioperative period. This probability is estimated at 13 % 
in patients who donated the amount of blood requested by the surgeon, and at 43 % in 
patients who did not5. The reason why some patients do not have a sufficient amount of 
AB at the end of the predonation procedure is that the hematopoietic response to iterative 
phlebotomy is too slow to reconstitute the initial Hb level before surgery, and that a 
sufficient EPO secretion occurs only for a certain degree of anemia, incompatible with 
ambulatory predonation procedure6,7.These patients are olten characterized by lower 
iron stores, and by a lower initial Hct4,5. 
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ln studies in which EPO is given during predonations, procedures are significantly more 
successful th an in patients receiving placebo. EPO doses necessary in this setting vary 
fram 100 U/Kg daily8 to more than 600 U/ Kg two or three times weekly4 
First of ail, EPO therapy, in addition to AB collection, was effective to increase the 
amount of blood collected, in terms of total red cell volume as weil as of the number of 
units obtained. In the main published study4, the number of patients unable to give 4 units 
or more was reduced from 29 % in the placebo group to 4 % in the EPO group. On the 
other hand, patients who received EPO seem to be at a lower risk of exposure to HB in 
the perioperative period. 
Another issue for these studies was to try to identify the patients for whom EPO 
treatment would be most beneficial, and some conclusions can be made. Patients who 
are scheduled to predonate large volumes of blood (>4 units) and are treated with EPO 
seem to be in better pre surgical condition (in terms of hemoglobin or Hct) than patients 
who only receive iron supplements. Moreover, the increase in red blood cell production 
induced by EPO and the mobilization of stored iron could lead anemic patients to be 
enrolled into AB predonation protocol despite the fact that their initial parameters are non 
suitable3, provided they are given adequate iron supplements. 
Ali patients included in AB predonation protocols with EPO should receive iron, orallyor 
sometimes IV6. This is necessary to achieve a sufficient iran supply to the bone marrow 
coming from both the reticuloendothelial system and the iran therapy. In the same way, 
iron supplements should be given to patients undergoing an AB predonation program, 
with or without EPO, especially to premenopausal women. For a routine use, the oral 
route is of course the simplest and the best in terms of side effects9, 1 a. 
The side effects of EPO are well-known and have mostly been seen in patients with 
renal failure. In published papers, patients with contraindications or in conditions known to 
be associated with poor response to EPO were excluded. No side effect was considered 
as EPO-dependent. In opposition to what happens in patients with renal failure, no 
significant change was noticed in arterial blood pressure. However, it remains necessary 
to fully assess the safety of EPO in perisurgical conditions. 
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IS EPO OF INTER EST FOR USE IN SURGERY AND/OR AUTOTRANSFUSION? 
ln order to lower HB exposure to surgical patients, several methods can be used. In a 
"blood sparing " policy, AB predeposit, combined with peroperative blood saving 
techniques can avoid many HB transfusions. In many cases, this reduction still remains 
unsatisfactory, because of the insufficient use of these techniques. The question of 
optimizing a global blood saving policy has to be continuously reviewed, to insure the 
mos! favorable attitude at any time. 
However, the routine procedures used in AB predeposit do not ensure that ail patients 
will receive only AB. In these cases, it seems to be interesting to use a technique that 
stimulates red cell production and improves the rate of AB collections. 
The cost-effectiveness of this approach cou Id also lead to future recommendations of 
reserving EPO only to well-targeted patients, who could receive a maximum benefit from 
it. 
ln summary in accordance with other authors 11, we think that EPO has a role in 
limitating HB exposure in patients who have to donate a large number of AB units, 
especially if the collection period is limited. On the other hand, patients having lower Hct at 
the start of a predeposit procedure, cou Id also be selected to receive EPO in order to 
insure an optimal collection to obtain the number of units ordered by the surgical team. 
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